The possible therapeutic role of curcumin and quercetin in the early-stage of COVID-19—Results from a pragmatic randomized clinical trial
Ikram Din Ujjan, Saeed Khan, Roohi Nigar, Hammad Ahmed, Sagheer Ahmad, Amjad Khan
Frontiers in Nutrition, doi:10.3389/fnut.2022.1023997
A (2023) The possible therapeutic role of curcumin and quercetin in the early-stage of COVID-19-Results from a pragmatic randomized clinical trial.
Ethics statement The study was approved by the Research Ethics Committee (REC), Liaquat University of Medical and Health Sciences (LUMHS), Jamshoro, Pakistan via Ref. No. LUMHS/REC/-137. The patients/participants provided their written informed consent to participate in this study.
Author contributions IU: study design, data collection, data interpretation, supervision, and critical revision of the manuscript. SK: study design, data interpretation, and manuscript revision. RN: data collection, supervision, and manuscript revision. HA: study administration, data collection, and manuscript
Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Aggarwal, Harikumar, Potential therapeutic effects of curcumin, the antiinflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases, Int J Biochem Cell Biol,
doi:10.1016/j.biocel.2008.06.010Ahmadi, Salari, Sharifi, Reihani, Rostamiani et al., Oral nano-curcumin formulation efficacy in the management of mild to moderate outpatient COVID-19: a randomized triple-blind placebo-controlled clinical trial, Food Sci Nutr,
doi:10.1002/fsn3.2226Babaei, Nassiri-Asl, Hosseinzadeh, Curcumin (a constituent of turmeric): new treatment option against COVID-19, Food Sci Nutr,
doi:10.1002/fsn3.1858Bernal, Da Silva, Musungaie, Kovalchuk, Gonzalez, None
Biancatelli, Berrill, Catravas, Marik, Derosa et al., Antiviral, immunomodulatory, and anticoagulant effects of quercetin and its derivatives: potential role in prevention and management of COVID-19, Front Immunol,
doi:10.1016/j.jpha.2021.09.009Bormann, Alt, Schipper, Van De Sand, Le-Trilling et al., Turmeric root and its bioactive ingredient curcumin effectively neutralize SARS-CoV-2 in vitro, Viruses,
doi:10.3390/v13101914Chabot, Huntwork, Honarkar ; Shafie, Taheri, Alijani et al., Effect of nanocurcumin supplementation on the severity of symptoms and length of hospital stay in patients with COVID-19: a randomized double-blind placebo-controlled trial, Phytother Res,
doi:10.1002/ptr.7374Chen, Li, Luo, Liu, Xu et al., Binding interaction of quercetin-3-beta-galactoside and its synthetic derivatives with SARS-CoV 3CL(pro): structure-activity relationship studies reveal salient pharmacophore features, Bioorg Med Chem,
doi:10.1016/j.bmc.2006.09.014Core, R: a language and environment for statistical computing
Docherty, Harrison, Green, Hardwick, Pius et al., Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study, BMJ,
doi:10.1136/bmj.m1985Dorward, Russell, Um, Elshani, Armstrong et al., Tissue-specific immunopathology in fatal COVID-19, Am J Respir Crit Care Med,
doi:10.1164/rccm.202008-3265OCGrasselli, Zangrillo, Zanella, Antonelli, Cabrini et al., Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the lombardy region, Italy, JAMA,
doi:10.1001/jama.2020.5394Group, Tocilizumab in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial, Lancet,
doi:10.1016/S0140-673600676-0Gupta, Gonzalez-Rojas, Juarez, Casal, Moya et al., Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab, N Engl J Med,
doi:10.1056/NEJMoa2107934Hammond, Leister-Tebbe, Gardner, Abreu, Wisemandle, Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19, N Engl J Med,
doi:10.1056/NEJMoa2118542Harwood, Danielewska-Nikiel, Borzelleca, Flamm, Williams et al., A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties, Food Chem Toxicol,
doi:10.1016/j.fct.2007.05.015Kalil, Patterson, Mehta, Tomashek, Wolfe et al., Baricitinib plus remdesivir for hospitalized adults with covid-19, N Engl J Med,
doi:10.1056/NEJMoa2031994Kamel, Abdelseed, Albalawi, Aslsalameen, Almutairi et al., Treatment of COVID-19 patients with quercetin: a prospective, single center, randomized, controlled trial, Turk J Biol,
doi:10.3906/biy-2104-16Khursheed, Singh, Wadhwa, Gulati, Awasthi, Enhancing the potential preclinical and clinical benefits of quercetin through novel drug delivery systems, Drug Discovery Today,
doi:10.1016/j.drudis.2019.11.001Lee, Yu, Trimpert, Benthani, Mairhofer et al., Virus-induced senescence is a driver and therapeutic target in COVID-19, Nature,
doi:10.1038/s41586-021-03995-1Leka, Hamann, Desdemoustier, Frédérich, Garigliany et al., In vitro antiviral activity against SARS-CoV-2 of common herbal medicinal extracts and their bioactive compounds, Phytother Res,
doi:10.3390/molecules26226900Lelli, Sahebkar, Johnston, Pedone, Curcumin use in pulmonary diseases: state of the art and future perspectives, Pharmacol Res,
doi:10.1016/j.phrs.2016.11.017Lucas, Wong, Klein, Castro, Silva et al., Longitudinal analyses reveal immunological misfiring in severe COVID-19, Nature,
doi:10.1038/s41586-020-2588-yMajeed, Nagabhushanam, Shah, Mundkur, A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of a nutritional supplement (ImmuActive(TM)) for COVID-19 patients, Evid Based Complement Alternat Med,
doi:10.1155/2021/8447545Moderbacher, Ramirez, Grifoni, Hastie, Weiskopf, Antigen-specific adaptive immunity to SARS-CoV-2 in Acute COVID-19 and associations with age and disease severity, Cell,
doi:10.1016/j.cell.2020.09.038Moghadamtousi, Kadir, Hassandarvish, Tajik, Abubakar et al., Review on antibacterial, antiviral, and antifungal activity of curcumin, BioMed Res Int,
doi:10.1155/2014/186864Munafò, Donati, Brindani, Ottonello, Armirotti et al., Quercetin and luteolin are single-digit micromolar inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase, Sci Rep,
doi:10.1038/s41598-022-14664-2Nguyen, Woo, Kang, Nguyen, Kim et al., Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease expressed in Pichia pastoris, Biotechnol Lett,
doi:10.1007/s10529-011-0845-8Pan, Fang, Zhang, Pan, Liu et al., Chinese herbal compounds against SARS-CoV-2: puerarin and quercetin impair the binding of viral S-protein to ACE2 receptor, Comput Struct Biotechnol J,
doi:10.1016/j.csbj.2020.11.010Pawar, Mastud, Pawar, Pawar, Bhoite et al., A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID-19 patients, Int Immunopharmacol,
doi:10.1016/j.intimp.2020.107088Petrillo, Orrù, Fais, Fantini, ; Abian et al., Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening, Int J Biol Macromol,
doi:10.1016/j.ijbiomac.2020.07.235Pierro, Derosa, Maffioli, Bertuccioli, Togni et al., Possible therapeutic effects of adjuvant quercetin supplementation against early-stage COVID-19 infection: a prospective, randomized, controlled, and open-label study, Int J Gen Med,
doi:10.2147/IJGM.S318949Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area, JAMA,
doi:10.1001/jama.2020.6775Rizzuti, Grande, Conforti, Jimenez-Alesanco, Ceballos-Laita et al., Rutin is a low micromolar inhibitor of SARS-CoV-2 main protease 3CLpro: implications for drug design of quercetin analogs, Biomedicines,
doi:10.3390/biomedicines9040375Rondanelli, Perna, Gasparri, Petrangolini, Allegrini et al., Promising effects of 3-month period of quercetin phytosome((R)) supplementation in the prevention of symptomatic COVID-19 disease in healthcare workers: a pilot study, Life,
doi:10.3390/life12010066Shohan, Nashibi, Mahmoudian-Sani, Abolnezhadian, Ghafourian et al., Oral co-supplementation of curcumin, quercetin, and vitamin D3 as an adjuvant therapy for mild to moderate symptoms of COVID-19-results from a pilot open-label, randomized controlled trial, Zaporizhia Med J,
doi:10.3389/fphar.2022.898062Weinreich, Sivapalasingam, Norton, Ali, Gao et al., REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19, N Engl J Med,
doi:10.1056/NEJMoa2035002Wen, Kuo, Jan, Liang, Wang et al., Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus, J Med Chem,
doi:10.1021/jm070295sYang, Wang, Long, Li, Quercetin: its main pharmacological activity and potential application in clinical medicine, Oxid Med Cell Longev,
doi:10.1155/2020/8825387Yang, Xie, Tu, Fu, Xu et al., The signal pathways and treatment of cytokine storm in COVID-19, Signal Trans Target Ther,
doi:10.1038/s41392-021-00679-0Zahedipour, Hosseini, Sathyapalan, Majeed, Jamialahmadi et al., Antiviral and immunomodulatory activity of curcumin: a case for prophylactic therapy for COVID-19, Front Pharmacol,
doi:10.1016/j.heliyon.2021.e06350{ 'indexed': {'date-parts': [[2024, 3, 4]], 'date-time': '2024-03-04T18:59:12Z', 'timestamp': 1709578752533},
'reference-count': 69,
'publisher': 'Frontiers Media SA',
'license': [ { 'start': { 'date-parts': [[2023, 1, 18]],
'date-time': '2023-01-18T00:00:00Z',
'timestamp': 1674000000000},
'content-version': 'vor',
'delay-in-days': 0,
'URL': 'https://creativecommons.org/licenses/by/4.0/'}],
'content-domain': {'domain': ['frontiersin.org'], 'crossmark-restriction': True},
'abstract': '<jats:sec><jats:title>Background</jats:title><jats:p>Curcumin (CUR) and quercetin (QUE), two '
'natural polyphenols, possess diverse biological activities including broad-spectrum '
'antiviral, antioxidant, and immunomodulatory effects. Both CUR and QUE have shown inhibition '
'of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in <jats:italic>in '
'vitro</jats:italic> '
'assays.</jats:p></jats:sec><jats:sec><jats:title>Objective</jats:title><jats:p>In the present '
'study we aimed to assess the possible treatment benefits of a combined curcumin and quercetin '
'(CUR-QUE) oral supplement, alongside standard of care (SOC), in the '
'<jats:italic>early-stage</jats:italic> COVID-19 '
'infection.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>This was an '
'exploratory, pragmatic, open-label, randomized controlled clinical trial, conducted at the '
'Department of Pathology, Liaquat University of Medical and Health Sciences, Jamshoro, PK. The '
'study compared the treatment effect of an oral CUR-QUE supplement '
'<jats:italic>plus</jats:italic> SOC vs. SOC alone, in the '
'<jats:italic>early-stage</jats:italic>/mild to moderately symptomatic COVID-19 outpatients. '
'Patients were randomized in a 1:1 ratio to CUR-QUE (<jats:italic>n</jats:italic> = 25) and '
'control (<jats:italic>n</jats:italic> = 25) treatment groups. The CUR-QUE supplementation '
'consisted of a daily intake of 168 mg curcumin and 260 mg quercetin, as two soft capsules, to '
'be taken twice a day at home for 14 '
'days.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>After one-week of '
'treatment, most of the patients in the CUR-QUE group showed an expedited clearance of the '
'viral infection i.e., 18 (72.0%) vs. 6 (24.0%) patients in the control group tested negative '
'for SARS-CoV-2 in the nasal-oropharyngeal swab reverse transcription-polymerase chain '
'reaction (RT-PCR) analysis (<jats:italic>p</jats:italic> = 0.0002). In addition, '
'COVID-19-associated acute symptoms were also speedily resolved in the CUR-QUE treated '
'patients, i.e., 10 (40.0%) vs. 4 (16.0%) patients in the control group '
'(<jats:italic>p</jats:italic> = 0.061). The CUR-QUE supplementation therapy was '
'well-tolerated by all 25 patients and no treatment-emergent effects or serious adverse events '
'were reported.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>The '
'results revealed in this exploratory study suggest a possible therapeutic role of curcumin '
'and quercetin in the <jats:italic>early-stage</jats:italic> of COVID-19. It is proposed that '
'the two agents possibly acting in synergy, interfere the SARS-CoV-2 replication, and thus '
'help a speedy recovery in the <jats:italic>early-stage</jats:italic> of COVID-19. Further '
'research is highly encouraged.</jats:p></jats:sec><jats:sec><jats:title>Clinical trial '
'registration</jats:title><jats:p><jats:ext-link>Clinicaltrials.gov</jats:ext-link>, '
'Identifier NCT04603690.</jats:p></jats:sec>',
'DOI': '10.3389/fnut.2022.1023997',
'type': 'journal-article',
'created': {'date-parts': [[2023, 1, 18]], 'date-time': '2023-01-18T06:41:35Z', 'timestamp': 1674024095000},
'update-policy': 'http://dx.doi.org/10.3389/crossmark-policy',
'source': 'Crossref',
'is-referenced-by-count': 2,
'title': 'The possible therapeutic role of curcumin and quercetin in the early-stage of COVID-19—Results '
'from a pragmatic randomized clinical trial',
'prefix': '10.3389',
'volume': '9',
'author': [ {'given': 'Ikram Din', 'family': 'Ujjan', 'sequence': 'first', 'affiliation': []},
{'given': 'Saeed', 'family': 'Khan', 'sequence': 'additional', 'affiliation': []},
{'given': 'Roohi', 'family': 'Nigar', 'sequence': 'additional', 'affiliation': []},
{'given': 'Hammad', 'family': 'Ahmed', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sagheer', 'family': 'Ahmad', 'sequence': 'additional', 'affiliation': []},
{'given': 'Amjad', 'family': 'Khan', 'sequence': 'additional', 'affiliation': []}],
'member': '1965',
'published-online': {'date-parts': [[2023, 1, 18]]},
'reference': [ { 'key': 'B1',
'doi-asserted-by': 'publisher',
'first-page': '3',
'DOI': '10.1097/jcma.0000000000000463',
'article-title': 'Clinical manifestation and disease progression in COVID-19 infection.',
'volume': '84',
'author': 'Tsai',
'year': '2021',
'journal-title': 'J Chin Med Assoc.'},
{ 'key': 'B2',
'doi-asserted-by': 'publisher',
'first-page': '463',
'DOI': '10.1038/s41586-020-2588-y',
'article-title': 'Longitudinal analyses reveal immunological misfiring in severe '
'COVID-19.',
'volume': '584',
'author': 'Lucas',
'year': '2020',
'journal-title': 'Nature.'},
{ 'key': 'B3',
'doi-asserted-by': 'publisher',
'first-page': '996',
'DOI': '10.1016/j.cell.2020.09.038',
'article-title': 'Antigen-specific adaptive immunity to SARS-CoV-2 in Acute COVID-19 and '
'associations with age and disease severity.',
'volume': '183',
'author': 'Rydyznski Moderbacher',
'year': '2020',
'journal-title': 'Cell.'},
{ 'key': 'B4',
'doi-asserted-by': 'publisher',
'first-page': '1671',
'DOI': '10.1016/j.cell.2021.02.029',
'article-title': 'COVID-19 and the human innate immune system.',
'volume': '184',
'author': 'Schultze',
'year': '2021',
'journal-title': 'Cell.'},
{ 'key': 'B5',
'doi-asserted-by': 'publisher',
'first-page': '861',
'DOI': '10.1016/j.cell.2021.01.007',
'article-title': 'Adaptive immunity to SARS-CoV-2 and COVID-19.',
'volume': '184',
'author': 'Sette',
'year': '2021',
'journal-title': 'Cell.'},
{ 'key': 'B6',
'doi-asserted-by': 'publisher',
'DOI': '10.1136/bmj.m1985',
'article-title': 'Features of 20 133 UK patients in hospital with covid-19 using the '
'ISARIC WHO clinical characterisation protocol: prospective '
'observational cohort study.',
'volume': '369',
'author': 'Docherty',
'year': '2020',
'journal-title': 'BMJ.'},
{ 'key': 'B7',
'doi-asserted-by': 'publisher',
'first-page': '1574',
'DOI': '10.1001/jama.2020.5394',
'article-title': 'Baseline characteristics and outcomes of 1591 patients infected with '
'SARS-CoV-2 admitted to ICUs of the lombardy region, Italy.',
'volume': '323',
'author': 'Grasselli',
'year': '2020',
'journal-title': 'JAMA.'},
{ 'key': 'B8',
'doi-asserted-by': 'publisher',
'first-page': '2052',
'DOI': '10.1001/jama.2020.6775',
'article-title': 'Presenting characteristics, comorbidities, and outcomes among 5700 '
'patients hospitalized with COVID-19 in the New York city area.',
'volume': '323',
'author': 'Richardson',
'year': '2020',
'journal-title': 'JAMA.'},
{ 'key': 'B9',
'doi-asserted-by': 'publisher',
'first-page': '250',
'DOI': '10.1002/jmv.26232',
'article-title': 'The cytokine storm and COVID-19.',
'volume': '93',
'author': 'Hu',
'year': '2021',
'journal-title': 'J Med Virol.'},
{ 'key': 'B10',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41392-021-00679-0',
'article-title': 'The signal pathways and treatment of cytokine storm in COVID-19.',
'volume': '6',
'author': 'Yang',
'year': '2021',
'journal-title': 'Signal Trans Target Ther.'},
{ 'key': 'B11',
'doi-asserted-by': 'publisher',
'first-page': '192',
'DOI': '10.1164/rccm.202008-3265OC',
'article-title': 'Tissue-specific immunopathology in fatal COVID-19.',
'volume': '203',
'author': 'Dorward',
'year': '2021',
'journal-title': 'Am J Respir Crit Care Med.'},
{ 'key': 'B12',
'doi-asserted-by': 'publisher',
'first-page': '509',
'DOI': '10.1056/NEJMoa2116044',
'article-title': 'Molnupiravir for oral treatment of covid-19 in nonhospitalized '
'patients.',
'volume': '386',
'author': 'Jayk Bernal',
'year': '2021',
'journal-title': 'N Engl J Med.'},
{ 'key': 'B13',
'doi-asserted-by': 'publisher',
'first-page': '1941',
'DOI': '10.1056/NEJMoa2107934',
'article-title': 'Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody '
'sotrovimab.',
'volume': '385',
'author': 'Gupta',
'year': '2021',
'journal-title': 'N Engl J Med.'},
{ 'key': 'B14',
'doi-asserted-by': 'publisher',
'first-page': '238',
'DOI': '10.1056/NEJMoa2035002',
'article-title': 'REGN-COV2, a neutralizing antibody cocktail, in outpatients with '
'covid-19.',
'volume': '384',
'author': 'Weinreich',
'year': '2020',
'journal-title': 'N Engl J Med.'},
{ 'key': 'B15',
'doi-asserted-by': 'publisher',
'first-page': '1397',
'DOI': '10.1056/NEJMoa2118542',
'article-title': 'Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19.',
'volume': '386',
'author': 'Hammond',
'year': '2022',
'journal-title': 'N Engl J Med.'},
{ 'key': 'B16',
'doi-asserted-by': 'publisher',
'first-page': '693',
'DOI': '10.1056/NEJMoa2021436',
'article-title': 'Dexamethasone in hospitalized patients with covid-19.',
'volume': '384',
'author': 'Collaborative Group',
'year': '2021',
'journal-title': 'N Engl J Med.'},
{ 'key': 'B17',
'doi-asserted-by': 'publisher',
'first-page': '1637',
'DOI': '10.1016/S0140-673600676-0',
'article-title': 'Tocilizumab in patients admitted to hospital with COVID-19: a '
'randomised, controlled, open-label, platform trial.',
'volume': '397',
'author': 'Collaborative Group',
'year': '2021',
'journal-title': 'Lancet.'},
{ 'key': 'B18',
'doi-asserted-by': 'publisher',
'first-page': '795',
'DOI': '10.1056/NEJMoa2031994',
'article-title': 'Baricitinib plus remdesivir for hospitalized adults with covid-19.',
'volume': '384',
'author': 'Kalil',
'year': '2020',
'journal-title': 'N Engl J Med.'},
{ 'key': 'B19',
'doi-asserted-by': 'publisher',
'first-page': '2911',
'DOI': '10.1002/ptr.6738',
'article-title': 'Potential effects of curcumin in the treatment of COVID-19 infection.',
'volume': '34',
'author': 'Zahedipour',
'year': '2020',
'journal-title': 'Phytother Res.'},
{ 'key': 'B20',
'doi-asserted-by': 'publisher',
'DOI': '10.3389/fphar.2021.675287',
'article-title': 'Curcumin as a potential treatment for COVID-19.',
'volume': '12',
'author': 'Rattis',
'year': '2021',
'journal-title': 'Front Pharmacol.'},
{ 'key': 'B21',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.heliyon.2021.e06350',
'article-title': 'Antiviral and immunomodulatory activity of curcumin: a case for '
'prophylactic therapy for COVID-19.',
'volume': '7',
'author': 'Thimmulappa',
'year': '2021',
'journal-title': 'Heliyon.'},
{ 'key': 'B22',
'doi-asserted-by': 'publisher',
'DOI': '10.3389/fimmu.2020.01451',
'article-title': 'Quercetin and vitamin C: an experimental, synergistic therapy for the '
'prevention and treatment of SARS-CoV-2 related disease (COVID-19).',
'volume': '11',
'author': 'Colunga Biancatelli',
'year': '2020',
'journal-title': 'Front Immunol.'},
{ 'key': 'B23',
'doi-asserted-by': 'publisher',
'first-page': '1230',
'DOI': '10.1002/ptr.6887',
'article-title': 'A role for quercetin in coronavirus disease 2019 (COVID-19).',
'volume': '35',
'author': 'Derosa',
'year': '2021',
'journal-title': 'Phytother Res.'},
{ 'key': 'B24',
'doi-asserted-by': 'publisher',
'first-page': '29',
'DOI': '10.1016/j.jpha.2021.09.009',
'article-title': 'Antiviral, immunomodulatory, and anticoagulant effects of quercetin and '
'its derivatives: potential role in prevention and management of '
'COVID-19.',
'volume': '12',
'author': 'Manjunath',
'year': '2022',
'journal-title': 'J Pharm Analy.'},
{ 'key': 'B25',
'doi-asserted-by': 'publisher',
'first-page': '5215',
'DOI': '10.1002/fsn3.1858',
'article-title': 'Curcumin (a constituent of turmeric): new treatment option against '
'COVID-19.',
'volume': '8',
'author': 'Babaei',
'year': '2020',
'journal-title': 'Food Sci Nutr.'},
{ 'key': 'B26',
'doi-asserted-by': 'publisher',
'first-page': '40',
'DOI': '10.1016/j.biocel.2008.06.010',
'article-title': 'Potential therapeutic effects of curcumin, the anti-inflammatory agent, '
'against neurodegenerative, cardiovascular, pulmonary, metabolic, '
'autoimmune and neoplastic diseases.',
'volume': '41',
'author': 'Aggarwal',
'year': '2009',
'journal-title': 'Int J Biochem Cell Biol.'},
{ 'key': 'B27',
'doi-asserted-by': 'publisher',
'DOI': '10.1186/1475-2891-13-11',
'article-title': 'Comparative absorption of curcumin formulations.',
'volume': '13',
'author': 'Jäger',
'year': '2014',
'journal-title': 'Nutr J.'},
{ 'key': 'B28',
'doi-asserted-by': 'publisher',
'first-page': '133',
'DOI': '10.1016/j.phrs.2016.11.017',
'article-title': 'Curcumin use in pulmonary diseases: state of the art and future '
'perspectives.',
'volume': '115',
'author': 'Lelli',
'year': '2017',
'journal-title': 'Pharmacol Res.'},
{ 'key': 'B29',
'doi-asserted-by': 'publisher',
'first-page': '4087',
'DOI': '10.1021/jm070295s',
'article-title': 'Specific plant terpenoids and lignoids possess potent antiviral '
'activities against severe acute respiratory syndrome coronavirus.',
'volume': '50',
'author': 'Wen',
'year': '2007',
'journal-title': 'J Med Chem.'},
{ 'key': 'B30',
'doi-asserted-by': 'publisher',
'DOI': '10.1155/2014/186864',
'article-title': 'Review on antibacterial, antiviral, and antifungal activity of '
'curcumin.',
'volume': '2014',
'author': 'Zorofchian Moghadamtousi',
'year': '2014',
'journal-title': 'BioMed Res Int.'},
{ 'key': 'B31',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.foodchem.2021.131594',
'article-title': 'Inhibition of the SARS-CoV-2 3CL(pro) main protease by plant '
'polyphenols.',
'volume': '373',
'author': 'Bahun',
'year': '2022',
'journal-title': 'Food Chem.'},
{ 'key': 'B32',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/v13101914',
'article-title': 'Turmeric root and its bioactive ingredient curcumin effectively '
'neutralize SARS-CoV-2 in vitro.',
'volume': '13',
'author': 'Bormann',
'year': '2021',
'journal-title': 'Viruses.'},
{ 'key': 'B33',
'doi-asserted-by': 'publisher',
'first-page': '3013',
'DOI': '10.1002/ptr.7463',
'article-title': 'In vitro antiviral activity against SARS-CoV-2 of common herbal '
'medicinal extracts and their bioactive compounds.',
'volume': '36',
'author': 'Leka',
'year': '2022',
'journal-title': 'Phytother Res.'},
{ 'key': 'B34',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/molecules26226900',
'article-title': 'Curcumin inhibits in vitro SARS-CoV-2 infection in vero E6 cells '
'through multiple antiviral mechanisms.',
'volume': '26',
'author': 'Marin-Palma',
'year': '2021',
'journal-title': 'Molecules.'},
{ 'key': 'B35',
'doi-asserted-by': 'publisher',
'first-page': '209',
'DOI': '10.1016/j.drudis.2019.11.001',
'article-title': 'Enhancing the potential preclinical and clinical benefits of quercetin '
'through novel drug delivery systems.',
'volume': '25',
'author': 'Khursheed',
'year': '2020',
'journal-title': 'Drug Discovery Today.'},
{ 'key': 'B36',
'doi-asserted-by': 'publisher',
'DOI': '10.1155/2020/8825387',
'article-title': 'Quercetin: its main pharmacological activity and potential application '
'in clinical medicine.',
'volume': '2020',
'author': 'Yang',
'year': '2020',
'journal-title': 'Oxid Med Cell Longev.'},
{ 'key': 'B37',
'doi-asserted-by': 'publisher',
'first-page': '8295',
'DOI': '10.1016/j.bmc.2006.09.014',
'article-title': 'Binding interaction of quercetin-3-beta-galactoside and its synthetic '
'derivatives with SARS-CoV 3CL(pro): structure-activity relationship '
'studies reveal salient pharmacophore features.',
'volume': '14',
'author': 'Chen',
'year': '2006',
'journal-title': 'Bioorg Med Chem.'},
{ 'key': 'B38',
'doi-asserted-by': 'publisher',
'first-page': '831',
'DOI': '10.1007/s10529-011-0845-8',
'article-title': 'Flavonoid-mediated inhibition of SARS coronavirus 3C-like protease '
'expressed in Pichia pastoris.',
'volume': '34',
'author': 'Nguyen',
'year': '2012',
'journal-title': 'Biotechnol Lett.'},
{ 'key': 'B39',
'doi-asserted-by': 'publisher',
'first-page': '266',
'DOI': '10.1002/ptr.7309',
'article-title': 'Quercetin and its derivates as antiviral potentials: a comprehensive '
'review.',
'volume': '36',
'author': 'Di Petrillo',
'year': '2022',
'journal-title': 'Phytother Res.'},
{ 'key': 'B40',
'doi-asserted-by': 'publisher',
'first-page': '1693',
'DOI': '10.1016/j.ijbiomac.2020.07.235',
'article-title': 'Structural stability of SARS-CoV-2 3CLpro and identification of '
'quercetin as an inhibitor by experimental screening.',
'volume': '164',
'author': 'Abian',
'year': '2020',
'journal-title': 'Int J Biol Macromol.'},
{ 'key': 'B41',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/biomedicines9040375',
'article-title': 'Rutin is a low micromolar inhibitor of SARS-CoV-2 main protease 3CLpro: '
'implications for drug design of quercetin analogs.',
'volume': '9',
'author': 'Rizzuti',
'year': '2021',
'journal-title': 'Biomedicines.'},
{ 'key': 'B42',
'doi-asserted-by': 'publisher',
'first-page': '283',
'DOI': '10.1038/s41586-021-03995-1',
'article-title': 'Virus-induced senescence is a driver and therapeutic target in '
'COVID-19.',
'volume': '599',
'author': 'Lee',
'year': '2021',
'journal-title': 'Nature.'},
{ 'key': 'B43',
'doi-asserted-by': 'publisher',
'first-page': '83',
'DOI': '10.2307/2986225',
'article-title': 'Graphical comparison of nonparametric curves.',
'volume': '45',
'author': 'Bowman',
'year': '1996',
'journal-title': 'Appl Statist.'},
{ 'key': 'B44',
'doi-asserted-by': 'publisher',
'first-page': '920',
'DOI': '10.2307/2532993',
'article-title': 'Non-parametric analysis of covariance.',
'volume': '51',
'author': 'Young',
'year': '1995',
'journal-title': 'Biometrics.'},
{ 'key': 'B45',
'year': '2015',
'journal-title': 'R: a language and environment for statistical computing.'},
{ 'key': 'B46',
'doi-asserted-by': 'publisher',
'DOI': '10.1038/s41598-022-14664-2',
'article-title': 'Quercetin and luteolin are single-digit micromolar inhibitors of the '
'SARS-CoV-2 RNA-dependent RNA polymerase.',
'volume': '12',
'author': 'Munafò',
'year': '2022',
'journal-title': 'Sci Rep.'},
{ 'key': 'B47',
'doi-asserted-by': 'publisher',
'first-page': '3518',
'DOI': '10.1016/j.csbj.2020.11.010',
'article-title': 'Chinese herbal compounds against SARS-CoV-2: puerarin and quercetin '
'impair the binding of viral S-protein to ACE2 receptor.',
'volume': '18',
'author': 'Pan',
'year': '2020',
'journal-title': 'Comput Struct Biotechnol J.'},
{ 'key': 'B48',
'doi-asserted-by': 'publisher',
'first-page': '4068',
'DOI': '10.1002/fsn3.2226',
'article-title': 'Oral nano-curcumin formulation efficacy in the management of mild to '
'moderate outpatient COVID-19: a randomized triple-blind '
'placebo-controlled clinical trial.',
'volume': '9',
'author': 'Ahmadi',
'year': '2021',
'journal-title': 'Food Sci Nutr.'},
{ 'key': 'B49',
'doi-asserted-by': 'publisher',
'DOI': '10.7759/cureus.17829',
'article-title': 'Turmeric as a possible treatment for COVID-19-induced anosmia and '
'ageusia.',
'volume': '13',
'author': 'Chabot',
'year': '2021',
'journal-title': 'Cureus.'},
{ 'key': 'B50',
'doi-asserted-by': 'publisher',
'first-page': '1013',
'DOI': '10.1002/ptr.7374',
'article-title': 'Effect of nanocurcumin supplementation on the severity of symptoms and '
'length of hospital stay in patients with COVID-19: a randomized '
'double-blind placebo-controlled trial.',
'volume': '36',
'author': 'Honarkar Shafie',
'year': '2022',
'journal-title': 'Phytother Res.'},
{ 'key': 'B51',
'doi-asserted-by': 'publisher',
'DOI': '10.1155/2021/8447545',
'article-title': 'A randomized, double-blind, placebo-controlled study to assess the '
'efficacy and safety of a nutritional supplement (ImmuActive(TM)) for '
'COVID-19 patients.',
'volume': '2021',
'author': 'Majeed',
'year': '2021',
'journal-title': 'Evid Based Complement Alternat Med.'},
{ 'key': 'B52',
'doi-asserted-by': 'publisher',
'DOI': '10.3389/fphar.2021.669362',
'article-title': 'Oral curcumin with piperine as adjuvant therapy for the treatment of '
'COVID-19: a randomized clinical trial.',
'volume': '12',
'author': 'Pawar',
'year': '2021',
'journal-title': 'Front Pharmacol.'},
{ 'key': 'B53',
'doi-asserted-by': 'publisher',
'first-page': '2616',
'DOI': '10.1002/ptr.7004',
'article-title': 'Oral nano-curcumin formulation efficacy in management of mild to '
'moderate hospitalized coronavirus disease-19 patients: an open label '
'nonrandomized clinical trial.',
'volume': '35',
'author': 'Saber-Moghaddam',
'year': '2021',
'journal-title': 'Phytother Res.'},
{ 'key': 'B54',
'doi-asserted-by': 'publisher',
'first-page': '1023',
'DOI': '10.1002/ptr.7375',
'article-title': 'Antiinflammatory potential of nano-curcumin as an alternative '
'therapeutic agent for the treatment of mild-to-moderate hospitalized '
'COVID-19 patients in a placebo-controlled clinical trial.',
'volume': '36',
'author': 'Asadirad',
'year': '2022',
'journal-title': 'Phytother Res.'},
{ 'key': 'B55',
'doi-asserted-by': 'publisher',
'first-page': '6417',
'DOI': '10.1002/ptr.7294',
'article-title': 'A triple-blind, placebo-controlled, randomized clinical trial to '
'evaluate the effect of curcumin-containing nanomicelles on cellular '
'immune responses subtypes and clinical outcome in COVID-19 patients.',
'volume': '35',
'author': 'Hassaniazad',
'year': '2021',
'journal-title': 'Phytother Res.'},
{ 'key': 'B56',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.eujim.2020.101122',
'article-title': 'Effects of nanocurcumin on inflammatory factors and clinical outcomes '
'in critically ill patients with sepsis: a pilot randomized clinical '
'trial.',
'volume': '36',
'author': 'Karimi',
'year': '2020',
'journal-title': 'Eur J Int Med.'},
{ 'key': 'B57',
'doi-asserted-by': 'publisher',
'first-page': '5325',
'DOI': '10.1002/jcp.30233',
'article-title': 'Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild '
'and severe COVID-19 patients.',
'volume': '236',
'author': 'Tahmasebi',
'year': '2021',
'journal-title': 'J Cell Physiol.'},
{ 'key': 'B58',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.lfs.2021.119437',
'article-title': 'Nanocurcumin improves Treg cell responses in patients with mild and '
'severe SARS-CoV2.',
'volume': '276',
'author': 'Tahmasebi',
'year': '2021',
'journal-title': 'Life Sci.'},
{ 'key': 'B59',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.intimp.2020.107088',
'article-title': 'Nano-curcumin therapy, a promising method in modulating inflammatory '
'cytokines in COVID-19 patients.',
'volume': '89',
'author': 'Valizadeh',
'year': '2020',
'journal-title': 'Int Immunopharmacol.'},
{ 'key': 'B60',
'doi-asserted-by': 'publisher',
'first-page': '2359',
'DOI': '10.2147/IJGM.S318720',
'article-title': 'Possible therapeutic effects of adjuvant quercetin supplementation '
'against early-stage COVID-19 infection: a prospective, randomized, '
'controlled, and open-label study.',
'volume': '14',
'author': 'Di Pierro',
'year': '2021',
'journal-title': 'Int J Gen Med.'},
{ 'key': 'B61',
'doi-asserted-by': 'publisher',
'first-page': '2807',
'DOI': '10.2147/IJGM.S318949',
'article-title': 'Potential clinical benefits of quercetin in the early stage of '
'COVID-19: results of a second, pilot, randomized, controlled and '
'open-label clinical trial.',
'volume': '14',
'author': 'Di Pierro',
'year': '2021',
'journal-title': 'Int J Gen Med.'},
{ 'key': 'B62',
'doi-asserted-by': 'publisher',
'DOI': '10.1101/2020.12.22.20245993',
'article-title': 'Evaluation of the effect of zinc, quercetin, bromelain and vitamin C on '
'COVID-19 patients.',
'author': 'Kamel',
'year': '2020',
'journal-title': 'medRxiv'},
{ 'key': 'B63',
'doi-asserted-by': 'publisher',
'first-page': '518',
'DOI': '10.3906/biy-2104-16',
'article-title': 'Treatment of COVID-19 patients with quercetin: a prospective, single '
'center, randomized, controlled trial.',
'volume': '45',
'author': 'Onal',
'year': '2021',
'journal-title': 'Turk J Biol.'},
{ 'key': 'B64',
'doi-asserted-by': 'publisher',
'DOI': '10.3390/life12010066',
'article-title': 'Promising effects of 3-month period of quercetin phytosome((R)) '
'supplementation in the prevention of symptomatic COVID-19 disease in '
'healthcare workers: a pilot study.',
'volume': '12',
'author': 'Rondanelli',
'year': '2022',
'journal-title': 'Life.'},
{ 'key': 'B65',
'doi-asserted-by': 'publisher',
'DOI': '10.1016/j.ejphar.2021.174615',
'article-title': 'The therapeutic efficacy of quercetin in combination with antiviral '
'drugs in hospitalized COVID-19 patients: a randomized controlled trial.',
'volume': '914',
'author': 'Shohan',
'year': '2022',
'journal-title': 'Eur J Pharmacol.'},
{ 'key': 'B66',
'doi-asserted-by': 'publisher',
'first-page': '636',
'DOI': '10.14739/2310-1210.2021.5.231714',
'article-title': 'Efficacy of quercetin in patients with pneumonia associated with '
'coronavirus disease (COVID-19).',
'volume': '23',
'author': 'Zupanets',
'year': '2021',
'journal-title': 'Zaporizhia Med J.'},
{ 'key': 'B67',
'doi-asserted-by': 'publisher',
'DOI': '10.3389/fphar.2022.898062',
'article-title': 'Oral co-supplementation of curcumin, quercetin, and vitamin D3 as an '
'adjuvant therapy for mild to moderate symptoms of COVID-19-results from '
'a pilot open-label, randomized controlled trial.',
'volume': '13',
'author': 'Khan',
'year': '2022',
'journal-title': 'Front Pharmacol.'},
{ 'key': 'B68',
'first-page': '2895',
'article-title': 'Phase I clinical trial of curcumin, a chemopreventive agent, in '
'patients with high-risk or pre-malignant lesions.',
'volume': '21',
'author': 'Cheng',
'year': '2001',
'journal-title': 'Anticancer Res.'},
{ 'key': 'B69',
'doi-asserted-by': 'publisher',
'first-page': '2179',
'DOI': '10.1016/j.fct.2007.05.015',
'article-title': 'A critical review of the data related to the safety of quercetin and '
'lack of evidence of in vivo toxicity, including lack of '
'genotoxic/carcinogenic properties.',
'volume': '45',
'author': 'Harwood',
'year': '2007',
'journal-title': 'Food Chem Toxicol.'}],
'container-title': 'Frontiers in Nutrition',
'original-title': [],
'link': [ { 'URL': 'https://www.frontiersin.org/articles/10.3389/fnut.2022.1023997/full',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2023, 1, 18]],
'date-time': '2023-01-18T06:41:39Z',
'timestamp': 1674024099000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.frontiersin.org/articles/10.3389/fnut.2022.1023997/full'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2023, 1, 18]]},
'references-count': 69,
'alternative-id': ['10.3389/fnut.2022.1023997'],
'URL': 'http://dx.doi.org/10.3389/fnut.2022.1023997',
'relation': {},
'ISSN': ['2296-861X'],
'subject': ['Nutrition and Dietetics', 'Endocrinology, Diabetes and Metabolism', 'Food Science'],
'container-title-short': 'Front. Nutr.',
'published': {'date-parts': [[2023, 1, 18]]}}
